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Objective: Peripheral arterial disease (PAD) is a common manifestation of systemic atherosclerosis. Over the last years,
several novel mediators relevant to the process of atherogenesis have been identified, but few and conflicting data are
available on the possible association with PAD symptoms. The aim of this study was to determine an extended
thrombophilic risk profile of patients with symptomatic PAD.
Methods: Two hundred eighty patients with symptomatic PAD admitted to the Department of Vascular Surgery of the
University of Florence were compared with 280 control subjects without PAD, matched for age and gender. The
following metabolic and genetic risk factors were evaluated: lipoprotein(a), homocysteine, antiphospholipid antibodies,
plasminogen activator inhibitor-1, factor V Leiden mutation, prothrombin variant, and 5,10-methylenetetrahydrofolate
reductase (MTHFR) C677T polymorphism.
Results:Multivariate logistic regression analysis, adjusted for traditional cardiovascular risk factors, showed a significant
association between PAD symptoms and prothrombin variant, altered levels of homocysteine, lipoprotein(a), plasmin-
ogen activator inhibitor-1, and antiphospholipid antibodies. Moreover, the presence of high levels of lipoprotein(a) and
another metabolic risk factor raised the likelihood of PAD symptoms (dyslipidemia and elevated lipoprotein[a]: odds
ratio [OR], 29; 95% confidence interval [CI], 6.2 to 136.2; P <.0001; hyperhomocysteinemia and elevated lipopro-
tein[a]: OR, 37.7; 95% CI, 3.7 to 381.5; P <.0001). A significant correlation between the number of altered
thrombophilic parameters and the Fontaine stage was observed (R  0.16; P  .006).
Conclusion: There is an independent association between altered levels of important thrombophilic risk factors and PAD
symptoms. The clinical significance of this association needs to be tested in prospective population-based trials. ( J Vasc
Surg 2005;41:255-60.)Peripheral arterial disease (PAD), defined as a chronic
obstruction of the arteries supplying the lower extremities,
is a common manifestation of systemic atherosclerosis.
Many longitudinal studies have demonstrated that both
symptomatic and asymptomatic PAD is associated with a
significantly increased risk for cardiovascular morbidity and
mortality.1
It has been clarified in the last few years that apart from
the traditional cardiovascular risk factors such as hyperten-
sion, smoking habit, dyslipidemia, and diabetes mellitus,
several novel mediators are relevant to the process of
atherogenesis.2 In particular, clinical research has been
focused on the possible role of thrombophilic risk factors.
Several clinical studies have shown a correlation between
elevated lipoprotein(a) (Lp[a]) and both coronary artery
disease3 and cerebrovascular disease.4 However, few data
are available regarding the role of Lp(a) levels on the
occurrence of PAD.5,6
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doi:10.1016/j.jvs.2004.11.015Case–control studies have indicated that many of the
proteins involved in fibrinolysis are related to the develop-
ment of atherosclerosis; in particular, the suppression of
fibrinolysis due to high plasma concentrations of plasmin-
ogen activator inhibitor-1 (PAI-1) has been associated with
the development of coronary artery disease.7 Limited and
incomplete data are available on the association between
PAI-1 levels and PAD.8,9
Immunologic mechanisms are increasingly being impli-
cated in the pathogenesis of atherosclerosis. Antiphospho-
lipid antibodies such as lupus anticoagulant and anticardio-
lipin antibodies (ACA) are a heterogeneous family of
autoantibodies directed against protein-phospholipid com-
plexes and have been associated with a number of disorders
characterized by underlying vascular damage. To date, the
association between antiphospholipid antibodies and PAD
has been suggested by reports describing cohorts of af-
fected patients.10
Some studies demonstrated a higher prevalence of
thrombophilic polymorphisms (prothrombin variant and
factor V Leiden mutation) in patients with PAD, but their
role as an independent risk factor has not been clearly
stated.11-12 Several studies13 have found increased homo-
cysteine (Hcy) levels in patients with atherosclerotic disease
affecting coronary, cerebral, and peripheral arteries. The
relation between hyperhomocysteinemia (HHcy) and PAD
has been recently confirmed.14 All these data derive from
studies performed on different patient populations. The
aim of this study was to determine an extended thrombo-
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tomatic PAD.
METHODS
Study population. The study population consisted of
280 patients (Fontaine stages II through IV) who were
referred to the Department of Vascular Surgery, University
of Florence for symptoms or signs suggestive of the pres-
ence of PAD. PADwas diagnosed when patients had typical
symptoms of intermittent claudication: cramping pain of
the calves or buttocks during exercise and an ankle-brachial
index (ABI) at rest of less than 0.90, calculated according to
American Heart Association recommendations.15 The con-
trol group consisted of 280 unrelated subjects without
PAD, matched for age and sex, who were recruited from
the staff of the University of Florence and from partners or
friends of patients.
Expert physicians performed a history and physical
examination to exclude any clinically apparent PAD. Pa-
tients and control subjects underwent blood sampling for
the search of several thrombophilic risk factors. All subjects
gave informed consent. The study complied with the Dec-
laration of Helsinki and was approved by the local ethics
committee.
All patients underwent clinical and instrumental evalu-
ation comprising an electrocardiogram, echocardiogram,
and duplex scanning with color-coded echo flow imaging
on carotid arteries. In patients whose symptoms were pos-
sibly related to ischemic heart disease, further investigations
were performed (echocardiogram on drug-induced stress
testing, myocardial scintigraphy, and coronary angiogra-
phy). Carotid stenosis, confirmed by computed tomogra-
phy angiography, was evaluated as diseased according to
the North American Symptomatic Carotid Evaluation Trial
(NASCET) criteria.16
Fontaine stages were assigned as follows: class IIa, mild
claudication with a walking distance of more than 200
meters; class IIb, severe claudication with a walking dis-
tance of less than 200 meters; class III, rest pain; class IV,
gangrene.
The study subjects were considered to have hyperten-
sion if they had been diagnosed as hypertensives according
to the guidelines of European Society of Hypertension/
European Society of Cardiology17 or were taking antihy-
pertensive drugs. A positive family history was defined as
the presence of at least one first-degree relative who had
developed cardiovascular disease before the age of 55 years
for men and 65 years for women. Dyslipidemia was defined
according to the Third Report of the National Cholesterol
Education Program (NCEP)18 and diabetes mellitus, in
agreement with the American Diabetes Association.19
Laboratory measurements. A 19-gauge needle was
used to collect venous blood from the antecubital vein
(without venous stasis) in tubes (Vacutainer, Becton Dick-
inson, Meylan, France) containing 0.129 mol/L concen-
tration of sodium citrate (final ratio with blood, 1:10) after
an overnight fasting.Plasma samples for the determination of Lp(a) and
PAI-1 levels were obtained after centrifugation (2000g for
10 minutes) and stored at 80°C. Sera for testing ACA
were obtained by centrifuging blood collected in evacuated
tubes without anticoagulant at 1300g for 10 minutes and
stored at 20°C. Stored plasma and serum were assayed
within 15 days for the determination of all parameters.
PAI-1 levels were determined by a chromogenic assay
(Spectrolyse [fibrin] Biopool, Umea, Sweden). Lp(a) was
assayed by enzyme-linked immunoabsorbent assay
(ELISA) (Mercodia Apo[a], Mercodia AB, Uppsala,
Sweden) The presence of ACA in serum was searched by
ELISA (First Cardiolipin, Eurospital, Trieste, Italy), and
ACA levels were reported in GPL units for immunoglobu-
lin (Ig) G and in MPL units for IgM.
To determine Hcy, whole venous blood was collected
in tubes containing ethylenediaminotetracetate (EDTA)
0.17mol/L, immediately put in ice, and centrifuged within
30 minutes at 4°C (1500g for 15 minutes). The superna-
tant was stored in aliquots at80°C until assay. The plasma
levels of total Hcy (free and protein bound) were deter-
mined by fluorescence polarization immunoassay (IMX
Abbott Laboratories, Oslo, Norway).
Factor V Leiden, prothrombin G20210A variant, and
5,10-methylenetetrahydrofolate reductase (MTHFR) gene
mutations were analysed as previously described.20-22
Statistical analysis. Values are expressed as mean 
standard deviation (SD) or median and range. Statistical
analyses were performed using the SPSS (Chicago, Ill)
software for Windows (Version 11.5). The nonparametric
Mann-Whitney test was used for comparisons between
single groups. The Kruskal-Wallis test was used for com-
parisons among different groups. The 2-test was used to
test for proportions and deviations of genotype distribution
from Hardy-Weinberg equilibrium.
HHcy was diagnosed when fasting plasma levels ex-
ceeded the 95th percentile ( 19mol/L inmen and 15
mol/L in women) of the distribution of values obtained
in our laboratory. A level of Lp(a) above 300 mg/L, which
is coincident with the 95th percentile of the reference
group of our laboratory and is widely accepted as the
cut-off of increased vascular risk,3 was considered abnor-
mal.
According to the literature, the cut-off of ACA to
discriminate normal and abnormal levels was set at 40MPL
or GPL units.23 Abnormally elevated levels of PAI-1 were
defined as levels of PAI-1 exceeding 15 IU/mL (ie,95th
percentile of the reference group of our laboratory).
The relationship between metabolic, genetic variables,
and PAD symptoms was determined by univariate logistic
regression analysis. Variables showing, at univariate analy-
sis, a statistical significant association with PAD symptoms
were introduced in a multivariate model to evaluate the
association with the disease after adjustment for traditional
risk factors of age, gender, hypertension, diabetes mellitus,
dyslipidemia, smoking habit, and familial history. The odds
ratio (OR) with 95% confidence interval (CI) was deter-
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significance.
RESULTS
Baseline characteristics and atherosclerotic traditional
risk factors in patients and controls are summarized in
Table I. No patient or control had clinical or laboratory
evidence of an autoimmune process: discoid rash, oral or
pharyngeal ulceration, frank arthritis, pleuritis, pericarditis,
persistent proteinuria, antibodies to native DNA, or anti-
extractable nuclear antigen antibodies. Moreover, no sign
of an active infectious process was detectable: fever, leuko-
cytosis, or increased erythrocyte sedimentation rate. We
observed, as expected, an increased prevalence of all tradi-
tional risk factors in symptomatic PAD patients versus
controls.
The prevalence of thrombophilic risk factors in both
populations is shown in Table II. The levels of all the
different parameters investigated but PAI-1, ACA, IgG,
and the prevalence of factor V Leiden were significantly
higher in symptomatic PAD patients than in controls. The
genotype distribution of MTHFR polymorphism was in
Hardy-Weinberg equilibrium in both groups.
Logistic regression analysis was performed to evaluate
the role of these parameters on the predisposition to symp-
tomatic PAD. The univariate analysis showed a significant
association between PAD symptoms and the presence of
altered parameters (MTHFR homozygosity: OR, 1.4; 95%
CI, 1.03 to 1.9; P  .03; Hhcy: OR, 3.1; 95% CI, 1.9 to
4.7; P  .0001; PAI-1: OR, 3.7; 95% CI, 2.2 to 6.0; P 
.0001; prothrombin variant: OR, 3.8; 95% CI, 1.2 to 12.4;
P .02; high levels of Lp[a]: OR, 3.9; 95% CI, 2.6 to 5.9;
P .0001; ACA positivity: OR, 13.6; 95% CI, 4.1 to 44.8;
P  .0001).
After adjustment for traditional cardiovascular risk fac-
tors, MTHFR homozygosity lost its associations with PAD
Table I. Characteristics of study population
Variable
Patients
(n  280)
Controls
(n  280)
Age (y) (%)* 69 (35-90) 70 (33-95)
Males (%) 216 (77.1) 216 (77.1)
Females (%) 64 (22.9) 64 (22.9)
Hypertension (%) 152 (54.3) 43 (15.4)†
Diabetes (%) 49 (17.5) 5 (1.8)†
Dyslipidemia (%) 118 (42.1) 32 (11.4)†
Smoking habit (%) 197 (70.4) 57 (20.4)†
Familial history (%)‡ 84 (30) 35 (12.5)†
Fontaine’s stage
IIa (%) 15 (5.4)
IIb (%) 175 (62.4)
III (%) 75 (26.8)
IV (%) 15 (5.4)
*Median and range.
†P  .0001, patients compared to controls.
‡History of PAD, myocardial infarction, unstable angina, coronary artery
bypass surgery, percutaneous coronary intervention, stroke.symptoms (Table III). High levels of Lp(a) and dyslipide-mia (n  43) raised the likelihood of PAD symptoms
(dyslipidemia: OR, 7.4; 95% CI, 4.2 to 12.9; P  .0001;
high levels of Lp[a] and dyslipidemia: OR, 29; 95% CI, 6.2
to 136.2; P  .0001). Similarly, high levels of Lp(a) and
HHcy (n  32) increased the likelihood of PAD symptoms
(OR, 37.7; 95% CI, 3.7 to 381.5; P  .0001).
In addition, the sample of patients was grouped by
Fontaine stages. No difference was found in ABI levels
among different Fontaine stages (P  0.3). A trend was
observed to an increase in Hcy, PAI-1, and Lp(a) levels
with PAD symptoms, but differences did not reach statisti-
cal significance (Table IV).
The thrombophilic profile of patients with PAD symp-
Table II. Prevalence of thrombophilic risk factors
Parameter
Patients
(n  280)
Controls
(n  280) P
Hcy, mol/L* 14.2 (2-102) 11 (6-70.6) .0001
HHcy (%) 85 (30.3) 35 (12.5) .0001
PAI-1 (IU/mL)† 11.4  9.1 9.6  3.4 .7
PAI-1  15 IU/mL (%) 74 (26.4) 25 (8.9) .0001
Lp(a), mg/L* 207 (1-1688) 85 (9-695) .0001
Lp(a)  300 mg/L (%) 110 (39.3) 40 (14.3) .0001
ACA IgG, UGPL† 10.3  8.3 6.1  3.7 .07
ACA IgM, UMPL† 5.8  4.6 4.1  1.6 .02
ACA (%) 13 (4.6) 2 (0.7) .005
FV Leiden (%)‡ 4 (1.4) 11 (3.9) .1
Prothrombin variant (%)‡ 15 (5.4) 4 (1.4) .02
MTHFR C677T
CC (%) 83 (29.6) 106 (37.9)
CT (%) 135 (48.2) 135 (48.2) .006
TT (%) 62 (22.2) 39 (13.9)
T allele 0.46 0.38 .2
ACA: IgG and/or IgM 40 UGPL/UMPL.
*Median and range.
†Mean  SD.
‡Heterozygous form.
Table III. Multivariate analysis*
Variable OR 95% CI P
Age 1.04 0.9-1.3 .6
Gender 0.9 0.5-1.5 .7
Familial history 2.7 1.6-4.7 .0001
Diabetes 4.8 2.2-10.1 .0001
Hypertension 6.0 3.7-9.8 .0001
Dyslipidemia 7.4 4.2-12.9 .0001
Smoking habit 9.9 6.1-16.1 .0001
MTHFR† 1.3 0.9-1.8 .2
HHcy 2.9 1.6-5.1 .0001
Lp(a)  300 mg/L 3.1 1.8-5.2 .0001
PAI-1  15 IU/mL 3.4 1.8-6.1 .0001
Prothrombin variant‡ 4.7 1.1-19.1 .03
ACA 8.6 1.4-51.3 .02
ACA: IgG and/or IgM 40 UGPL/UMPL.
*Adjusted for age, gender, hypertension, diabetes, dyslipidemia, smoking
habit and familial history.
†TT vs. CTCC.
‡Heterozygous form.toms was assessed by grouping the positivity of all emerging
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factor was present in 112 patients (40%), whereas 2 or more
were present in 88 patients (31.4%). We similarly grouped
the patients for the presence of traditional cardiovascular
risk factors. One traditional risk factor was present in 69
patients (24.7%), and 2 or more risk factors were present in
202 (72.1%).
Furthermore, a statistically significant correlation be-
tween the number of altered thrombophilic parameters and
Fontaine stages was observed (R  0.16; P  .006).
DISCUSSION
Only a limited number of studies during the last few
years have evaluated the possible role of different thrombo-
philic risk factors in the pathogenesis of symptomatic PAD;
moreover, all the available studies have assessed one or just
a few thrombophilic factors, frequently in a limited number
of patients. The present study has thoroughly evaluated the
most important thrombophilic risk factors in a considerable
number of patients with symptomatic PAD and has re-
ported significant and independent associations between
these factors and PAD symptoms. Of particular relevance is
the relation between ACA and PAD symptoms.
Although arterial thrombosis in the lower limbs is rare
in patients with antiphospholipid syndrome, several studies
smaller than ours have reported an increased prevalence of
ACA positivity in PAD.10,24 Moreover, previous studies
have demonstrated that ACA may confer an increased risk
of mortality in PAD patients.10 More recently, the presence
of antiphospholipid antibodies in patients undergoing
lower extremity bypass operations was observed to be a
significant independent risk factor for the progression of
PAD.25 However, whether ACA are secondary to the vas-
cular disease or play a direct role in its pathogenesis can be
evaluated only by prospective studies. Our data further
support the need for prevention trials to assess the efficacy
and safety of anticoagulant therapy in symptomatic PAD
patients with ACA.
A significantly higher prevalence of the prothrombin
G20210A variant was found in our patients than in con-
trols, suggesting that this variant is a moderate risk factor
for symptomatic PAD in our cohort. Our data contrast with
the conclusion of a recent meta-analysis that the overall
association of prothrombin variant and arterial events is
Table IV. Thrombophilic risk factors by Fontaine’s stages
Fontaine’s
stage
Lp(a) (mg/L),
median (range)
Hcy (mol/L),
median (range)
PAI-1 (IU
mean 
IIa (n  15) 128 (1-1235) 13.4 (8-36.3) 9.5  9
IIb (n  175) 200 (1-1688) 14.2 (4-88.2) 11.2  8
III (n 75) 217 (1-1150) 14.1 (2-65) 11.1  9
IV (n  15) 310 (11-924) 17.3 (4-102) 16.7  1
P† .4 .6 .1
*Heterozygous form.
†Kruskal-Wallis test.
‡Chi-square test.only modest.26 However, only one study performed inPAD was included in the meta-analysis.27 Our finding, on
the contrary, has been very recently confirmed by Reny
et al.28
Concerning factor V Leiden mutation, we did not
observe an increased prevalence in patients versus controls.
This issue has been studied in the past years with contrast-
ing results.11,27,29 Moreover, the largest study available in
the literature, like ours, could not confirm an increased
prevalence of factor V Leiden in PAD.27
In our study, PAI-1 has a relevant role and has been
found to be associated with PAD symptoms independently
of smoking habit, lipid abnormalities, and diabetes melli-
tus, conditions known to be associated to increased PAI-1
plasma levels. Clinically, there is abundant evidence that
associations between cardiovascular disease and PAI-1 are
mediated through clustering with other vascular risk mark-
ers in the presence of insulin resistance. PAI-1 levels are in
part genetically determined; however, physical exercise and
body weight reduction have been reported to be able to
decrease PAI-1 levels.
Plasma Lp(a) levels are genetically determined and only
minimally affected by age, sex, and environmental factors.
There is clinical evidence of an association between high
plasma Lp(a) levels and atherosclerotic disease,3-4 but con-
trasting data on the role of increased levels of Lp(a) as an
independent risk factor for different clinical manifestations
of atherothrombosis have been reported. Some studies
found an increased prevalence of Lp(a) in PAD patients 5-6;
in keeping with these results, our study showed an associ-
ation between increased levels of Lp(a) and PAD symp-
toms, after adjustment for traditional cardiovascular risk
factors.
A number of studies have reported an increased
prevalence of HHcy in PAD patients,13-14 whereas data
from the Physicians’ Health Study (obtained from a
patient sample which is 50% of ours) did not show a role
of HHcy as a risk factor for future PAD in apparently
healthy individuals.2 Interestingly, our results indicate a
relationship between Hcy levels and PAD symptoms as
also suggested by Taylor et al.30 Elevations in plasma
Hcy may be caused by genetic defects in the enzymes
involved in Hcy metabolism, the main one being
MTHFR, or by nutritional deficiencies in vitamin cofac-
tors, or both. In particular, a thermolabile variant of the
uping
, ACA IgM (UMPL),
mean  SD
ACA IgG (UGPL),
mean  SD
Prothrombin
variant, n (%)*
4.3  3.3 8.8  7.7 1 (6.7)
6.1  5.8 10.5  8.9 6 (3.4)
5.8  4.7 9.9  8.0 3 (4)
4.5  4.3 11.9  11.4 –
.9 .3 .2 	gro
/mL)
SD
.0
.8
.3
0.8MTHFR enzyme (C677T) has been correlated with
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we could not observe an independent role of MTHFR
polymorphism as a risk factor for PAD symptoms.
Some limitations can be identified in this study. First,
because of its cross-sectional design, the study is unable
to determine if the altered hemostatic parameters are
causally related to the presence and severity of PAD
symptoms. A population study on patients with an ABI
of less than 0.9 compared with a truly healthy control
group would be the best way to truly test this hypothesis.
Second, patients were all symptomatic and therefore, not
really representative of the broader PAD population.
Third, we were not able to perform a Doppler examina-
tion with ABI measurements in the control group.
Fourth, we did not evaluate the role of vitamin deficiency
in this population as cause of HHcy.
We did, however, find a number of thrombophilic
alterations in patients with symptomatic PAD, which
may contribute to the pathophysiology of this condition,
or to its thrombotic complications, or both. Further-
more, this is the first report clearly showing that the
contemporary presence of high Lp(a) levels and either
HHcy or dyslipidemia raised the likelihood of PAD
symptoms. This may have practical implications in the
management of these patients because Lp(a) is not a
modifiable risk factor, whereas both HHcy and dyslipi-
demia can be corrected by dietary and pharmacologic
interventions.
In particular, plasma Hcy is easy to measure, and the
treatment to reduce it is easy and inexpensive. Therefore,
the potential impact of such a treatment on symptomatic
PAD population is huge, and intervention trials are ur-
gently required. In the meantime, the fact that Hcy effects
appear to be even stronger in the presence of other risk
factors suggests the opportunity of its correction by vitamin
supplementation in high-risk patients.
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